Safety data sheet

3E Acquires Workplace Safety Provider, Quick-FDS

Retrieved on: 
Wednesday, April 3, 2024
Pharmaceutical, Health, Media, Communications, Chemicals, Plastics, Supply Chain Management, Manufacturing, Retail, 3E, Proskauer Rose, Safety, Safety data sheet, SDS, Growth, LLP, Acquisition, REACH, Shearman & Sterling, Chemical industry, EHS, Medical device

3E, the leading global provider of intelligent compliance solutions for chemical and workplace safety, product stewardship, and sustainable supply chains, has completed its previously announced acquisition of Quick-FDS, the leading provider of workplace safety solutions in France.

Key Points: 
  • 3E, the leading global provider of intelligent compliance solutions for chemical and workplace safety, product stewardship, and sustainable supply chains, has completed its previously announced acquisition of Quick-FDS, the leading provider of workplace safety solutions in France.
  • Quick-FDS partners with both global manufacturers and downstream users of chemical products, providing mission-critical solutions that enable improved regulatory compliance and workplace safety.
  • “We are thrilled to welcome Quick-FDS’ team, clients and partners into the broader 3E organization.
  • REACH regulations in the EU require all suppliers of chemicals to provide a unique Safety Data Sheet for each chemical substance to their customers.

3E in the Process of Acquiring French Workplace Safety Platform, Quick-FDS

Retrieved on: 
Wednesday, November 8, 2023
Professional Services, Business, Environmental, Social and Governance (ESG), Environment, Sustainability, Consulting, JP, Headquarters, European Economic Area, Saint Denis, Catalog, Chemical industry, 3E, WEKA, Safety data sheet, Workplace, Organization, Acquisition, REACH, Multimedia, SDS, Safety, LLP, Proskauer Rose, Shearman & Sterling, Chemical safety, Medical device, EU

Headquartered in Saint-Denis, France, Quick-FDS works with global manufacturers and users of chemical products, offering a full suite of solutions that enable improved regulatory compliance and workplace safety.

Key Points: 
  • Headquartered in Saint-Denis, France, Quick-FDS works with global manufacturers and users of chemical products, offering a full suite of solutions that enable improved regulatory compliance and workplace safety.
  • Quick-FDS’ market-leading solution enables superior regulatory compliance and efficiency, allowing customers to focus on their business instead of navigating ever-changing regulations.
  • Robin Dualé, President of WEKA in France, said “The combination of 3E and Quick-FDS would unite two of the most sophisticated SDS management solutions globally.
  • The transaction would be subject to customary conditions including the prior staff representatives’ consultation and regulatory approvals.

Dominion Energy Announces Retirements of Two Directors, Election of Two New Independent Directors as Part of Continuing Board Refreshment

Retrieved on: 
Friday, November 3, 2023
Finance, Research, Dominion Energy, Chemical safety, Altria, Public policy, Retirement, Phillips, Norfolk Southern Railway, J. P. Morgan, Annual general meeting, Wind, Questar Corporation, Internet, Compensation, United States Department of Energy, Columbia University, DOE, Safety data sheet, United, USS Pintado, Sustainability, Policy, Engineer, Corporation, Phillips 66, Center on Global Energy Policy, Transport, Woodruff Arts Center, NYSE, Government, Drew University, MBA, Trustee, Public sector, Southern Company Gas, American University, Foreign policy, General counsel, Eastman Chemical Company, Holding company, Management, Renewable energy, LNG, Science, United States Navy

Jibson was elected to the board in 2016 after the completion of the combination of Dominion Energy and Questar Corporation, where he was chairman, president, and chief executive officer.

Key Points: 
  • Jibson was elected to the board in 2016 after the completion of the combination of Dominion Energy and Questar Corporation, where he was chairman, president, and chief executive officer.
  • "Ron and Mike have served Dominion Energy's shareholders with distinction," said Robert M. Blue, chair, president and chief executive officer.
  • The company also announced that the board of directors has elected two new independent directors, Vanessa L. Allen Sutherland and Paul M. Dabbar.
  • Those elections are effective Dec. 1, 2023, and part of the company's ongoing commitment to strong corporate governance and regular board refreshment of its board of directors.

EFFICIENCY MEETS SAFETY: CHEMTREC® INTRODUCES SAFETY DATA SHEET AUTHORING SERVICE TO SIMPLIFY COMPLIANCE

Retrieved on: 
Monday, October 30, 2023
SDS, Reading, Learning, Safety data sheet, Safety, Heart, Research, Satellite navigation device, Medical device

WASHINGTON, Oct. 30, 2023 /PRNewswire/ -- CHEMTREC, the leading provider of emergency response information for hazardous materials incidents, proudly introduces its new comprehensive Safety Data Sheet (SDS) Authoring service.

Key Points: 
  • WASHINGTON, Oct. 30, 2023 /PRNewswire/ -- CHEMTREC, the leading provider of emergency response information for hazardous materials incidents, proudly introduces its new comprehensive Safety Data Sheet (SDS) Authoring service.
  • Designed to simplify and streamline the SDS creation process, CHEMTREC's new offering combines specialized knowledge, a commitment to quality assurance, and dedication to compliance.
  • At the heart of CHEMTREC's SDS Authoring services is a team of Certified SDS Registered Professional (SDSRP) specialists.
  • If you are interested in learning more about CHEMTREC's SDS Authoring services and streamlining your SDS creation process while delivering quality, compliance, and cost-effectiveness, please visit https://www.chemtrec.com/sds-authoring .

Axiom Highlighting Fusion eClinical Suite at DIA 2023

Retrieved on: 
Friday, June 23, 2023
Clinical data management, Safety, Xiaogang Ma, Booth, Research, Metric, Suite, Safety data sheet, Axiom, DIA, Unified, EDC, Pharmaceutical industry

Axiom’s proprietary Fusion eClinical Suite enables effective collaboration and accelerated decision-making through real-time actionable data.

Key Points: 
  • Axiom’s proprietary Fusion eClinical Suite enables effective collaboration and accelerated decision-making through real-time actionable data.
  • “Axiom is thrilled to be back at the DIA Annual Meeting, highlighting Fusion eClinical Suite, the pre-eminent and global Unified eClinical platform.
  • Fusion eClinical Suite can help deliver eClinical and study operations needs.
  • To register for this event, please visit: https://www.diaglobal.org/en/flagship/dia-2023
    Learn more about Axiom’s Fusion eClinical Suite: https://www.axiommetrics.com/fusion-eclinical-suite/

Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, May 8, 2023
Exercise, OPA, Research and development, P-value, Solar eclipse of March 31, 2090, Investment, IPD, Safety, Pneumococcal conjugate vaccine, Ageing, G&A, Element, Breakthrough therapy, Genetically modified bacteria, PCV20, Safety data sheet, Administration, SAN, Peterborough, Growth, R, PCV, STS, FDA, General Administration of Sport of China, Immunization, IND, Vaccine, Pharmaceutical industry, Cryptocurrency, PCV15, Infant

-- $949.9 Million in Cash, Cash Equivalents and Investments as of March 31, 2023, Excluding Net Proceeds of $545.1 Million from Recent Public Offering --

Key Points: 
  • VAX-24, the Company’s lead, broad-spectrum 24-valent pneumococcal conjugate vaccine (PCV) candidate, is being studied for the prevention of IPD.
  • Submission of the adult IND application to the FDA and announcement of subsequent FDA clearance in the second half of 2023.
  • The March 31, 2023 amount excludes the $545.1 million in estimated net proceeds from the follow-on offering completed in April 2023.
  • Net Loss: For the three months ended March 31, 2023, net loss was $60.5 million, compared to $39.0 million for the same period in 2022.

 Origami Risk Expands Online Environmental and Chemical Safety and Compliance Tools for EHS Professionals

Retrieved on: 
Tuesday, February 14, 2023
Software, Insurance, Environment, Environmental Issues, Chemicals, Plastics, Professional Services, Technology, Manufacturing, Origami, Software as a service, Safety data sheet, Water, Reputational damage, Safety, Hazardous waste, Documentation, Chemical substance, SDS, PSM, EHS, Process safety management, Health, Atmosphere, STP, Occupational Safety and Health Act 1994, Calendar, Chemical safety, Risk management, Machine shop

Origami Risk, the industry-leading risk, safety and insurance Software as a Service (SaaS) technology firm, today announced the expansion of online environmental and chemical offerings to help environmental, health and safety (EHS) leaders remain compliant with evolving regulations, reinforce safety and reduce hazards.

Key Points: 
  • Origami Risk, the industry-leading risk, safety and insurance Software as a Service (SaaS) technology firm, today announced the expansion of online environmental and chemical offerings to help environmental, health and safety (EHS) leaders remain compliant with evolving regulations, reinforce safety and reduce hazards.
  • “Along with ongoing imperatives to maintain or enhance safety, reduce risks, drive efficiency, support productivity, and achieve operational excellence, EHS professionals face an evolving and increasingly complex regulatory framework — especially with regard to environmental and chemical management,” said Sean Salvas, senior market strategy lead-EHS at Origami Risk.
  • “In collaboration with our EHS clients, we have developed a variety of tools that enable EHS professionals to facilitate environmental and chemical safety and manage compliance with greater precision, speed, efficiency and transparency.”
    Specifically, Origami’s chemical and environmental tools support EHS professionals in the following areas:
    Environmental permits.
  • Centralized digital management of environmental permits enable EHS teams to ensure environmental regulatory compliance, avoid shutdowns, fines, and reputational damage.

Prime Medicine Announces Recent Progress and Highlights 2023 Strategic Priorities

Retrieved on: 
Monday, January 9, 2023
Disease, FRDA, Genome, Cystic fibrosis transmembrane conductance regulator, Swelling, CGD, Safety data sheet, Respiratory tract, GAA, Tissue, Cystic fibrosis, CD34, CMC, AAV, Heart, Failure rate, CFTR, Mitochondrion, Culture, DNA, LNP, Safety, Mutation, IPSC, Gene editing, Central nervous system, Hepatocyte, Patient, Degenerative disease, CF, Bronchiole, Neuron, PCSK9, Ataxia, Liver, Human, FXN, Inflammation, Chronic granulomatous disease, Eye, Investment, Prime editing, Vaccine, Pharmaceutical industry, Medical device, IND, WD, Frataxin

CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today provided an update on recent advancements of its Prime Editing technology and progress across its initial pipeline of eighteen programs, and outlined its strategic priorities and expected milestones for 2023.

Key Points: 
  • Today, Prime Medicine announced new preclinical data demonstrating that Prime Editing-mediated removal of pathological repeats in vitro results in correction of hypermethylation at the FXN gene, restoring genetic function back to wild-type levels.
  • Off-target Safety Data: Prime Medicine is progressing a comprehensive suite of assays to evaluate the potential off-target activity of its Prime Editors.
  • Prime Medicine is using PCSK9 as a model system for developing its modular LNP delivery platform to the liver.
  • Prime Medicine expects the following activities and next steps to drive the Prime Editing platform forward:
    Nominate first development candidate for CGD in 1Q 2023.

gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma

Retrieved on: 
Wednesday, September 28, 2022
Cytokine release syndrome, OS, Safety, Nivolumab, HLA, Patient, Clinical trial, U.S. Securities and Exchange Commission, DLT, Nasdaq, CRS, Malignant transformation, Research, Large-cell lung carcinoma, Ipilimumab, PR, Risk, COVID-19, Ovary, Survival, NSCLC, Company, Growth, Cmax, Annual report, DCR, RECIST, Investor, DL, Cholangiocarcinoma, Ovarian cancer, Neoplasm, Population, MPM, Review, TCR, Progression-free survival, Tissue, Security (finance), GLOBE, Cancer, Infrared spectroscopy correlation table, Safety data sheet, Pancreatic cancer, Private Securities Litigation Reform Act, Therapy, Breast cancer, ORR, Metastasis, Cell, Cyber Safety Review Board, Secondary, Truc, PFS, Mesothelioma, Webcast, Pharmaceutical industry, Medical imaging, Vaccine

CAMBRIDGE, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced positive topline results from the Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors, with some patients still being monitored for clinical response or stable disease.

Key Points: 
  • By BICR, the ORR was 21% among patients with malignant pleural/peritoneal mesothelioma (MPM) and 29% among those with ovarian cancer.
  • These are remarkable data in the context of solid tumors where there have been significant challenges with current CAR-T therapies.
  • The trial is enrolling patients with either mesothelin expressing non-small cell lung cancer (NSCLC), ovarian cancer, cholangiocarcinoma, or malignant pleural/peritoneal mesothelioma (MPM).
  • Mesothelin is a cell-surface glycoprotein highly expressed in a wide range of solid tumors, including malignant pleural/peritoneal mesothelioma, ovarian cancer, cholangiocarcinoma, breast cancer, pancreatic cancer and others.

Groundbreaking USW Guide on 'Stop Work Authority' Will Protect Workers

Retrieved on: 
Wednesday, July 20, 2022
Rubber industry in Malaysia, Warner Sallman, List of environmental ministries, Public sector, Injury, Workplace (Health, Safety and Welfare) Regulations 1992, SWA, Michaels, Dan Sullivan (U.S. senator), National Labor Relations Act of 1935, Fatality, United Steelworkers, Explosion, Metal, OSHA, Occupational safety and health, Glass, Chemical safety, Paper, Multimedia, Assistant, Firestone Tire and Rubber Company, Barack Obama, Newborn Screening Saves Lives Act of 2007, Mining, Labour, USW, George Washington University School of Engineering and Applied Science, Death, Senate, Safety data sheet, Public health, Health insurance, Management, Online shopping, Safety, Health

PITTSBURGH, July 20, 2022 /PRNewswire/ -- The United Steelworkers (USW) today announced the publication of a new groundbreaking guide from its Health, Safety, and Environment Department.

Key Points: 
  • PITTSBURGH, July 20, 2022 /PRNewswire/ -- The United Steelworkers (USW) today announced the publication of a new groundbreaking guide from its Health, Safety, and Environment Department.
  • "The United Steelworkers is proud to issue this path-breaking guide," said USW International President Tom Conway.
  • "In addition, workers often face challenges, including retaliation, in their efforts to stop unhealthy or unsafe work."
  • Debra Coyle, executive director of the New Jersey Work Environment Council, the nation's longest-standing state labor-environmental alliance, said that the guide can help protect workers and communities.